Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD studyShow others and affiliations
2015 (English)In: Journal of Lipid Research, ISSN 0022-2275, E-ISSN 1539-7262, Vol. 56, no 3, p. 674-681Article in journal (Refereed) Published
Abstract [en]
Specialized proresolving mediators (SPMs) induce resolution of inflammation. SPMs are derivatives of n-3 and n-6 PUFAs and may mediate their beneficial effects. It is unknown whether supplementation with PUFAs influences the production of SPMs. Alzheimer's disease (AD) is associated with brain inflammation and reduced levels of SPMs. The OmegAD study is a randomized, double-blind, and placebo-controlled clinical trial on AD patients, in which placebo or a supplement of 1.7 g DHA and 0.6 g EPA was taken daily for 6 months. Plasma levels of arachidonic acid decreased, and DHA and EPA levels increased after 6 months of n-3 FA treatment. Peripheral blood mononuclear cells (PBMCs) were obtained before and after the trial. Analysis of the culture medium of PBMCs incubated with amyloid-β 1-40 showed unchanged levels of the SPMs lipoxin A4 and resolvin D1 in the group supplemented with n-3 FAs, whereas a decrease was seen in the placebo group. The changes in SPMs showed correspondence to cognitive changes. Changes in the levels of SPMs were positively correlated to changes in transthyretin. We conclude that supplementation with n-3 PUFAs for 6 months prevented a reduction in SPMs released from PBMCs of AD patients, which was associated with changes in cognitive function.
Place, publisher, year, edition, pages
American Society for Biochemistry and Molecular Biology, 2015. Vol. 56, no 3, p. 674-681
Keywords [en]
Alzheimer’s disease, amyloid β, clinical trials, docosahexaenoic acid, fatty acid, fish oil, inflammation, lipoxin, nutrition, peripheral blood mononuclear cell, resolvin
National Category
Medical and Health Sciences Neurology
Identifiers
URN: urn:nbn:se:oru:diva-74048DOI: 10.1194/jlr.P055418ISI: 000350345900019PubMedID: 25616438Scopus ID: 2-s2.0-84925345642OAI: oai:DiVA.org:oru-74048DiVA, id: diva2:1313958
Funder
Swedish Research CouncilStockholm County CouncilGun och Bertil Stohnes StiftelseStiftelsen Gamla Tjänarinnor
Note
Funding agencies:
Pronova Biocare A/S
Chinese Scholarship Council
Swedish Alzheimer Foundation
2019-05-072019-05-072022-02-11Bibliographically approved